Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1)
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Thrombosis and Haemostasis"
DOI: 10.1111/jth.14660
Abstract: The current standard of care for patients with hemophilia A is regular prophylaxis with factor VIII (FVIII) administered intravenously. Interest in subcutaneous (s.c.) administration, to potentially increase convenience, reduce the treatment burden and improve compliance,… read more here.
Keywords: subcutaneous turoctocog; preliminary efficacy; efficacy subcutaneous; immunogenicity safety ... See more keywords
The feasibility and efficacy of subcutaneous plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA–identical sibling donors: results of the HOVON‐107 study
Sign Up to like & getrecommendations! Published in 2019 at "Transfusion"
DOI: 10.1111/trf.15037
Abstract: Plerixafor (PFX) mobilizes CD34+ cells into circulation by disrupting the CXCR4 binding of the hematopoietic stem cell in its bone marrow niche. read more here.
Keywords: mobilization peripheral; efficacy subcutaneous; subcutaneous plerixafor; stem ... See more keywords
Efficacy of subcutaneous house dust mite immunotherapy in patients with moderate to severe allergic rhinitis.
Sign Up to like & getrecommendations! Published in 2022 at "Immunotherapy"
DOI: 10.2217/imt-2021-0353
Abstract: Aim: To evaluate the efficacy of subcutaneous immunotherapy (SCIT) for the treatment of allergy to house dust mites (HDM) in adults with moderate/severe allergic rhinitis (AR). Methods: Patients sensitized to HDM were randomized to SCIT… read more here.
Keywords: immunotherapy; efficacy subcutaneous; house dust; group ... See more keywords